Alexion
Also known as: Achillion, a wholly owned subsidiary of Alexion | Alexion | Alexion Antibody Technologies | ALEXION PHARM | Alexion Pharmaceuticals | Alexion Pharmaceuticals, Inc. | Alexion Pharma GmbH | Alexion Pharma Italy s.r.l. | ALEXION PHARMS INC
Highest phase reached
Phase 4
First clinical trial
Jan 1, 2002First marketed drug
Mar 16, 2007First NDA
Mar 16, 2007Last known activity
Dec 31, 2025
Timeline
1990s
- Jan 1, 1992
Alexion— Founded
2000s
- Jan 1, 2000
Proliferon Inc.— Acquired
- Dec 31, 2006
Alexion— Defunct
2010s
- Jan 31, 2011
Taligen Therapeutics— Acquired
- Feb 10, 2011
Orphatech Pharmaceuticals, GmbH— Acquired
- Feb 7, 2012
Enobia Pharmaceuticals— Acquired
- Jun 23, 2015
Synageva Biopharma— Acquired
- Apr 11, 2018
Wilson Therapeutics AB— Acquired
- Sep 26, 2018
Syntimmune, Inc.— Acquired
- Dec 21, 2018
ravulizumab-cwvz— Marketing Organization
- Dec 21, 2018
ravulizumab-cwvz— NDA Organization
- Oct 16, 2019
Achillion Pharmaceuticals— Acquired
2020s
- May 4, 2020
Portola Pharmaceuticals— Acquired - Oct 13, 2020
AstraZeneca— Acquired By
Drugs by trial phase (94 distinct, 265 trials)
Phase 4 (10 own, 10 via acquisition)
Phase 3 (3 own, 9 via acquisition)
Phase 2 (11 own, 22 via acquisition)
Indications
Approved for
Studied for
- Acute Lung Injury
- Amyloidosis
- Amyotrophic Lateral Sclerosis
- Anemia
- Anemia, Hemolytic
- Anemia, Hemolytic, Autoimmune
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Antiphospholipid Syndrome
- Asthma
- Atypical Hemolytic Uremic Syndrome
- Azotemia
- Cardiomyopathies
- Cholesterol Ester Storage Disease
- Coronary Artery Disease
- Death
- Delayed Graft Function
- Disease
- End Stage Liver Disease
- Failure to Thrive
- Geographic Atrophy
- Glomerulonephritis
- Glomerulonephritis, IGA
- Glomerulonephritis, Membranoproliferative
- Graft vs Host Disease
- Hemoglobinuria
- Hemoglobinuria, Paroxysmal
- Hemolysis
- Hemolytic-Uremic Syndrome
- Hepatolenticular Degeneration
- Hypophosphatasia
- Kidney Diseases
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Liver Diseases
- Lung Injury
- Lupus Nephritis
- Macular Degeneration
- Metal Metabolism, Inborn Errors
- Motor Neuron Disease
- Mucopolysaccharidoses
- Mucopolysaccharidosis III
- Multiple Myeloma
- Muscle Weakness
- Myasthenia Gravis
- Neoplasms, Plasma Cell
- Nephritis
- Neuromyelitis Optica
- Pneumonia
- Pneumonia, Viral
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Sclerosis
- Syndrome
- Thrombotic Microangiopathies
- Vascular Diseases
- Vasculitis
- Ventricular Dysfunction
- Ventricular Dysfunction, Left
- Wolman Disease
Marketed drugs (5)
Subsidiaries (9 direct, 10 total across the full acquisition tree)
Recent trials (50)
- NCT05686564Lead sponsorN/A—
- NCT04802083Lead sponsorN/A—
- NCT04355494Lead sponsorN/A—
- NCT05982938Lead sponsorN/A—
- NCT04757259Lead sponsorN/A—
- NCT07221838Lead sponsorPhase 4Dec 31, 2025
- NCT07218887Lead sponsorPhase 1/Phase 2Dec 31, 2025
- NCT07308574Lead sponsorPhase 4Dec 26, 2025
- NCT07160608Lead sponsorPhase 2Oct 31, 2025
- NCT07037420Lead sponsorPhase 2Oct 28, 2025
- NCT07306949Lead sponsorPhase 4Oct 1, 2025
- NCT07157787Lead sponsorPhase 2Sep 19, 2025
- NCT07213583CollaboratorPhase 2Aug 28, 2025
- NCT07081646Lead sponsorPhase 1/Phase 2Aug 18, 2025
- NCT07024563Lead sponsorPhase 3Jun 14, 2025
Details
- Founded
- New Haven, CT, US Jan 1, 1992
- First NDA
- Mar 16, 2007
- Last known activity
- Dec 31, 2025
Designations held
- Orphan drug
- Fast track
- Breakthrough therapy